CD274 and early-onset autosomal dominant Alzheimer disease: Independently of the above critical issues, the regimen of weekly treatment for “chronic PD-1/PD-L1 immune checkpoint blockade,” has not only never been suggested as a therapeutic protocol for achieving long-term effects in Alzheimer's disease, but is in contrast to previous studies using PD-1 or PD-L1 blocking antibodies (Baruch et al., 2016; Rosenzweig et al., 2019).